Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CB-011 in relapsed/refractory multiple myeloma
NCT05722418Phase 1Recruiting
- Sponsor
- Caribou Biosciences
- Start
- Feb 2023
- Primary completion
- Dec 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CB-011 in multiple myeloma (MM) (2 arms), sponsored by Caribou Biosciences. Primary endpoints: Dose Limiting Toxicities at 28 days and Overall Response Rate at 12 months. Started Feb 2023; status: recruiting.
02
Drugs
CB-011
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05722418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05722418.